全球首个！美国FDA批准艾伏尼布用于治疗IDH1突变胆管癌

Cholangiocarcinoma is a rare malignant tumor that occurs in the bile ducts inside and outside the liver. An estimated 8,000 people in the United States are diagnosed with cholangiocarcinoma each year. Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor that has been approved by the U.S. FDA for the treatment of previously treated adult patients with locally advanced or metastatic cholangiocarcinoma who carry IDH1 mutations detected by an FDA-approved test. This means that (ivosidenib) has become the first drug in the world to be approved by the US FDA for targeted treatment of patients with IDH1-mutated cholangiocarcinoma.

The world's first randomized phase 3 clinical trial evaluated the effectiveness of ivosidenib in patients with previously treated cholangiocarcinoma carrying IDH1 mutations. The trial results showed that compared with the placebo group, the ivosidenib treatment group achieved the primary endpoint of progression-free survival (PFS) and greatly reduced the patient's risk of disease progression or death. At the same time, ivosidenib also improved the overall survival (OS) of patients. It can be seen that ivosidenib has a significant effect in treating cholangiocarcinoma. It can reduce the patient's pain, improve the patient's quality of life and disease progression, and prolong the patient's survival.

Avosidenib usage and dosage

The recommended dosage of ivonib is: 500 mg orally daily, with or without food, until disease progression or intolerable toxicity occurs. Patients should avoid high-fat diet while receiving ivosidenib. During actual medication, the dosage can be adjusted according to the patient's physical condition and tolerance to the drug.

The above is the introduction to ivosidenib. If patients have any other questions about the drug, they can contact the medical companion service at any time.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: